Skip to main content

Table 2 Ongoing clinical studies

From: The story of artesunate–mefloquine (ASMQ), innovative partnerships in drug development: case study

Country Study type Phase n Primary objective
Nigeria Sickle cell proguanil vs AS+MQ vs SP+AQ 1/2 270 Safety and tolerability of bi-monthly intermittent preventive treatment with AS+MQ or sulphadoxine-pyrimethamine + amodiaquine compared to proguanil for prevention of malaria and related complications in patients with sickle cell anaemia
Amazon Basin Efficacy 2/3 100 Evaluate the effectiveness of ASMQ FDC to treat uncomplicated falciparum malaria in the Juruá Valley
Burkina Faso Pregnant women 2/3 48 PK of ASMQ FDC in pregnant women
Burkina Faso, Ghana, Malawi and Zambia Pregnant women: ASMQ vs DHA-PQ vs ASAQ vs AL 3 3500 Efficacy and safety of four ACTs (artemether-lumefantrine, amodiaquine-artesunate, mefloquine-artesunate and dihydroartemisinin-piperaquine) in pregnant women with P. falciparum malaria
Tanzania, Burkina Faso and Kenya Efficacy, safety and PK in children ASMQ vs AL 4 940 Efficacy, safety and population pharmacokinetics ASMQ FDC in African children vs artemether-lumefantrine
Thailand Pregnant women: ASMQ vs DHA-PQ vs AL 3 1,000 Randomized trial of three ACT for malaria in pregnancy (DMA)
Brazil Efficacy and safety P. vivax: ASMQ+PQ vs CQ+PQ vs AL+PQ 3 264 Efficacy and safety for treating P. vivax: ASMQ+PQ vs CQ+PQ vs AL+PQ